oru.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature
Dept Med, Div Gastroenterol, Örebro Univ Hosp, Örebro, Sweden.ORCID-id: 0000-0002-1046-383x
Örebro universitet, Hälsoakademin.
Dept Cardiol, Örebro Univ Hosp, Örebro, Sweden.
Örebro universitet, Hälsoakademin.
2011 (engelsk)Inngår i: Journal of Gastrointestinal and Liver Diseases, ISSN 1841-8724, E-ISSN 1842-1121, Vol. 20, nr 1, s. 77-80Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Bosentan is an endothelin receptor antagonist approved for treatment of pulmonary arterial hypertension. Mild liver reactions occur in about 10% of treated patients but severe hepatotoxicity is rare. We present clinical data and treatment outcome of a severe drug induced liver injury due to bosentan in a patient with non-cirrhotic portopulmonary hypertension. After 18 months of uncomplicated therapy with bosentan 125 mg b.i.d., the patient developed a severe mixed hepatic injury. Serum levels of bilirubin were 316 µmol/l (ref. value <20 micromol/l), AST 14 µkat/l (ref. value < 0.9 µkat/l), ALT 10 µkat/l (ref. value < 0.9 µkat/l), ALP 8 µkat/l (ref. value <1.8 µkat/l) and INR 1.8 (ref. value 0.9-1.1). Complete diagnostic work-up disclosed no other cause of hepatotoxicity. Treatment with prednisolone 40 mg/day in tapering doses was ultimately added and the patient made a full recovery. Subsequent treatment with sildenafil and ambrisentan for pulmonary arterial hypertension was well tolerated and liver function tests have remained normal during 12 months' follow-up. A review of the literature revealed three other women with severe hepatotoxicity due to bosentan. Bosentan may cause severe liver injury, even after long uneventful therapy, and current recommendations on regular monitoring of liver function tests are reinforced. Ambrisentan may be a therapeutic alternative in patients with pulmonary arterial hypertension and hepatotoxicity by bosentan.

sted, utgiver, år, opplag, sider
Cluj: Medical University Press , 2011. Vol. 20, nr 1, s. 77-80
HSV kategori
Forskningsprogram
Medicin
Identifikatorer
URN: urn:nbn:se:oru:diva-24212ISI: 000289044100014PubMedID: 21451802OAI: oai:DiVA.org:oru-24212DiVA, id: diva2:542806
Tilgjengelig fra: 2012-08-03 Laget: 2012-08-03 Sist oppdatert: 2019-03-04bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

PubMedhttp://www.jgld.ro/2011/1/14.pdf

Personposter BETA

Eriksson, CarlGustavsson, AndersTysk, Curt

Søk i DiVA

Av forfatter/redaktør
Eriksson, CarlGustavsson, AndersTysk, Curt
Av organisasjonen
I samme tidsskrift
Journal of Gastrointestinal and Liver Diseases

Søk utenfor DiVA

GoogleGoogle Scholar

pubmed
urn-nbn

Altmetric

pubmed
urn-nbn
Totalt: 336 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf